Quote Request
iPSC-Based Vaccine Development for Pancreatic Cancer
Welcome to Alfa Cytology, your premier destination for groundbreaking cancer treatment solutions. We specialize in preclinical research for iPSC-based vaccine development, providing innovative approaches to combat pancreatic cancer. Our expertise and advanced technologies ensure that your research is supported by comprehensive and cutting-edge scientific methodologies.
Overview of iPSC-Based Vaccine for Pancreatic Cancer
iPSC vaccination teaches the immune system to recognize a wide range of non-mutated tumor antigens, potentially making it effective for malignancies with low tumor mutational burdens. Researchers discovered that iPSCs, reprogrammed from mature skin or blood cells, exhibit gene expression patterns similar to cancer cells but not normal tissue. They hypothesized that an iPSC-based cancer vaccine could generate a robust immune response against various malignancies.
Fig. 1 The iPSC-based cancer vaccine development (Ouyang X, et al., 2021)
In previous study, researchers developed a cancer vaccine using mouse iPSCs and tested it in a pancreatic ductal adenocarcinoma model. The iPSCs were irradiated to prevent division and combined with CpG, an adjuvant that enhances immune responses. The combination led to 75% of the mice completely rejecting the injected pancreatic cancer cells.
This therapy significantly increased the activation of CD8+ killer T-cells and stimulated the production of inflammatory molecules like IFN-gamma and IL-2, indicating comprehensive immune activation. It also reduced regulatory T-cells, which suppress immune responses in the tumor microenvironment, and inhibited tumor-promoting T-helper 17 cells.
Fig. 2 A murine iPSC vaccine prevents tumor formation in vivo (Ouyang X, et al., 2021)
In general, iPSC vaccination presents a broad spectrum of non-mutated tumor antigens, potentially making this approach applicable to pancreatic ductal adenocarcinoma and other cancers with low tumor mutational burdens.
Our Services
Induced pluripotent stem cell (iPSC)-based vaccines represent a novel and promising strategy for treating pancreatic cancer. iPSCs are reprogrammed from adult cells to an embryonic-like pluripotent state, allowing them to differentiate into any cell type, including cancer cells. By using iPSCs to generate pancreatic cancer cells, we can create personalized vaccines that present a broad array of tumor-associated antigens (TAAs) to the immune system. This method aims to induce a robust and targeted immune response against pancreatic cancer.
iPSC-based Vaccine Preparation
iPSCs have immunogenic potential and express tumor-associated antigens (TAAs) that can be recognized and responded to by the adaptive immune system. Our vaccine preparation generally consists of sorting murine iPSCs for pluripotency, irradiation, suspension in adjuvant solution, and quality control.
iPSC-based Vaccine Validation
Based on our advanced preclinical modeling platform, we can evaluate the antitumor efficacy and safety of iPSC-based cancer vaccines in multiple models of PC (including in vitro and in vivo PC models) and facilitate the development of iPSC-based vaccines. With reliable data and scientifically rigorous analysis, our services can not only help our customers assess the optimal vaccination schedule, but also provide additional information for in-depth studies of iPSC-based vaccines.
- Evaluate the efficacy of iPSC-based cancer vaccines
- Assess the immune-stimulatory effects of iPSC-based cancer vaccines
- Define the mechanism underlying the effectiveness
Workflow of Our Services
Why Choose Us?
Tailored Solutions
Advanced Technology
Professional Expertise
Collaborative Approach
As a leading company in preclinical research for cancer immunotherapy, Alfa Cytology is committed to advancing the science of pancreatic cancer treatment. Our specialized iPSC-based vaccine development services provide critical insights and data, propelling the journey towards effective therapeutic solutions. Contact us today to learn more about how our preclinical expertise can support your research endeavors.
Reference
- Ouyang X, Liu Y, Zhou Y, Guo J, Wei TT, Liu C, Lee B, Chen B, Zhang A, Casey KM, Wang L, Kooreman NG, Habtezion A, Engleman EG, Wu JC. Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer. Stem Cell Reports. 2021 Jun 8;16(6):1468-1477.
